Authoring CMC Module 3 and Module 2.3 (QOS) for Drug Products
What It Is: Equally critical to any marketing authorization application is the Drug Product CMC section — covering formulation development, manufacturing process, excipients, controls, analytical methods, container closure system, and stability data. This section must be authored with precision, scientific clarity, and full alignment to current ICH and regional regulatory expectations.
ReguLinx provides expert Drug Product CMC writing, reviewing, and updating services across all major dosage forms and product types, including solid oral, parenteral, biological, and complex drug products.
Who It Is For: Pharmaceutical companies preparing NDA, ANDA, BLA, MAA, or IND submissions; companies updating Drug Product CMC documentation for lifecycle management; and organizations seeking an independent expert review of existing documents before submission.
New Drug Application (NDA) — US FDA
What It Is: An NDA is the formal vehicle through which a drug sponsor formally proposes that the US FDA approve a new pharmaceutical for sale and marketing in the United States. The CMC section of an NDA must provide comprehensive evidence that the drug product can be manufactured consistently to meet its approved specifications.
ReguLinx provides CMC module authoring, coordination, and review support for NDA submissions — working alongside your regulatory, clinical, and manufacturing teams to produce a complete, well-organized, and agency-ready dossier.
Abbreviated New Drug Application (ANDA) — US FDA
What It Is: An ANDA is filed with the US FDA to obtain approval for a generic drug product. The ANDA must demonstrate that the proposed generic drug is bioequivalent to the reference listed drug and that its CMC sections meet FDA’s rigorous quality standards.
Our team has extensive ANDA CMC experience and can author or review Module 3 documentation, perform gap analyses, and respond to FDA information requests to help generic manufacturers achieve approval efficiently.
Biologics License Application (BLA) — US FDA
What It Is: A BLA is required to obtain FDA licensure for biological products, including therapeutic proteins, monoclonal antibodies, vaccines, blood and blood products. BLA CMC sections are significantly more complex than those for small molecules, requiring detailed characterization data, process controls, and analytical comparability studies.
ReguLinx’s team has direct biologics regulatory experience and can support BLA CMC authoring, review, and responses to FDA questions — for both original applications and post-approval supplements.
Marketing Authorization Application (MAA) — EMA
What It Is: An MAA is submitted to the European Medicines Agency for approval to market a medicinal product across EU member states via the centralized procedure. The quality module (Module 3) of a European MAA must comply with the EU CTD format and EMA-specific guidelines.
We provide comprehensive MAA CMC support, including Module 3 authoring, QOS preparation, expert review, and responses to CHMP or assessor questions — supporting both new chemical entities and biosimilar applications.
Japan New Drug Application (JNDA) — PMDA
What It Is: The Japan New Drug Application (JNDA) is the regulatory submission required by PMDA for approval of new drugs in Japan. Japan has specific regulatory requirements, including unique data requirements, document format preferences, and review processes that differ from ICH norms.
ReguLinx’s Japan regulatory specialists prepare JNDA CMC documentation in line with PMDA expectations, coordinate with Japanese translation professionals, and provide support through the PMDA review process.
Investigational New Drug (IND) Application — US FDA
What It Is: Before clinical trials can begin in the United States, a sponsor must file an IND application with FDA. The CMC section of an IND must provide enough manufacturing and quality information to assure FDA that the investigational product is adequately characterized and can be safely administered to humans.
ReguLinx provides IND CMC authoring support for early-phase investigational products — ensuring your IND is complete, compliant, and sets a strong foundation for later NDA or BLA submissions.
Briefing Books and Scientific Advisory Meetings
What It Is: Regulatory briefing books are prepared for Type A, B, or C FDA meetings or equivalent agency interactions. These documents articulate your regulatory strategy, data package, and key questions for agency feedback — and must be scientifically rigorous and clearly presented.
Our team prepares CMC sections of briefing books and supports preparation for scientific advisory meetings, helping clients enter agency interactions well-prepared and with a clear regulatory strategy.
CMC Gap Analysis — Drug Product
A systematic assessment of existing Drug Product CMC documentation against the expectations of your target regulatory agency. We deliver a prioritized gap report and remediation plan to bring your dossier to full submission readiness before filing.
Response to Health Authority Questions — Drug Product
Expert preparation of responses to health authority information requests, complete responses, and deficiency letters related to Drug Product CMC sections. We work rapidly and methodically to protect your approval timeline.